
Browsing restrictions can be lifted for a fee.
BioLASCO Taiwan Co., Ltd. provides bio-materials and surgical services in Taiwan and internationally. It breeds and produces SPF laboratory rats and mice, including outbreed stocks, inbreed strains, and immune deficient models, as well as offers special animal model services. The company also provides endotoxin detection, animal heath diagnostic, and serological kits, as well as biological indicators. In addition, it offers IVC systems and ventilated houses equipment; professional and automated animal watering systems; transponders; chlorine dioxide gas generators; mouse and rat tail cuff blood pressure systems, analgesia equipment, and animal behavioral equipment; metabolism and behavior systems, and trackers; XPERT cabinet X-ray systems; automatic cleaning equipment; workstations; isolation chambers; and foggers. BioLASCO Taiwan Co., Ltd. was founded in 1990 and is based in Taipei, Taiwan.
6662
樂斯科
-0.51%
(-0.01)
The most recent financial report for 樂斯科 (6662) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6662's short-term business performance and financial health. For the latest updates on 6662's earnings releases, visit this page regularly.
According to historical valuation range analysis, 樂斯科 (6662)'s current price-to-earnings (P/E) ratio is 15.37, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 樂斯科 (6662) reported an Operating Profit of 11.89M with an Operating Margin of 18.8% this period, representing a decline of 10.79% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 樂斯科 (6662) announced revenue of 63.22M, with a Year-Over-Year growth rate of -8.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 樂斯科 (6662) held Total Cash and Cash Equivalents of 72.26M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 樂斯科 (6662) achieved the “three margins increasing” benchmark, with a gross margin of 41.65%%, operating margin of 18.8%%, and net margin of 12.83%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6662's profit trajectory and future growth potential.
According to the past four quarterly reports, 樂斯科 (6662)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
樂斯科 (6662)'s Free Cash Flow (FCF) for the period is 1.35M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 70.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.